Hudson Amanda L, Cho Angela, Colvin Emily K, Hayes Sarah A, Wheeler Helen R, Howell Viive M
Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW 2065, Australia.
School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.
Cancers (Basel). 2024 Mar 6;16(5):1069. doi: 10.3390/cancers16051069.
Brain cancer is a devastating and life-changing disease. Biomarkers are becoming increasingly important in addressing clinical issues, including in monitoring tumour progression and assessing survival and treatment response. The goal of this study was to identify prognostic biomarkers associated with glioma progression. Discovery proteomic analysis was performed on a small cohort of astrocytomas that were diagnosed as low-grade and recurred at a higher grade. Six proteins were chosen to be validated further in a larger cohort. Three proteins, CA9, CYFIP2, and LGALS3BP, were found to be associated with glioma progression and, in univariate analysis, could be used as prognostic markers. However, according to the results of multivariate analysis, these did not remain significant. These three proteins were then combined into a three-protein panel. This panel had a specificity and sensitivity of 0.7459 for distinguishing between long and short survival. In silico data confirmed the prognostic significance of this panel.
脑癌是一种具有毁灭性且会改变人生的疾病。生物标志物在解决临床问题方面正变得越来越重要，包括监测肿瘤进展以及评估生存情况和治疗反应。本研究的目的是识别与胶质瘤进展相关的预后生物标志物。对一小群被诊断为低级别但复发时为高级别的星形细胞瘤进行了发现性蛋白质组分析。选择了六种蛋白质在更大的队列中进一步验证。发现三种蛋白质，即碳酸酐酶9（CA9）、细胞质脆性X智力低下蛋白2（CYFIP2）和3-磷酸半乳糖苷结合蛋白（LGALS3BP）与胶质瘤进展相关，并且在单变量分析中可作为预后标志物。然而，根据多变量分析结果，这些不再具有显著性。然后将这三种蛋白质组合成一个三蛋白组。该蛋白组区分长生存期和短生存期的特异性和敏感性为0.7459。计算机模拟数据证实了该蛋白组的预后意义。
Zotero 插件
